Assessment of Patient-Reported Outcomes in Sarcoidosis Patients: A Review
Main Article Content
Abstract
Patient-reported outcomes are standardized reports provided by patients about their own health-related quality of life, health status, their symptoms or functional status associated with the health care or treatment they have received. Patient-reported outcomes are measured by questionnaires that are scientific instruments validated in different clinical conditions. The aim of this review is to provide the updated information on patient-reported outcomes use in assessment of pharmacotherapy effects in patients with pulmonary sarcoidosis. Sarcoidosis is a chronic disease in which treatment decisions for the majority of patients are based predominantly on health-related quality of life measurements. It is a chronic multisystem granulomatous inflammatory disease of unknown origin that is most commonly present in the lungs but may also involve any other organ. Therefore, it is important not only to assess their pulmonary symptoms like dyspnea or cough, but also those that originate from other organs and even constitutional ones, like fatigue or depression.
We separately presented the health-related quality of life and health status, as well as symptom-specific patient-reported outcomes used in sarcoidosis patients that measure fatigue, dyspnea, cough, and depression. Since corelations between objective and subjective disease outcomes in sarcoidosis patients are often mild or moderate or even do not exist at all, a consensus has emerged to use both of these outcomes in clinical trials and routine practice management. Therefore, the World Association of Sarcoidosis and other Granulomatous Disorders recommended that all research studies should incorporate health-related quality of life measurement.
Article Details
How to Cite
GVOZDENOVIC, Branislav S. et al.
Assessment of Patient-Reported Outcomes in Sarcoidosis Patients: A Review.
Medical Research Archives, [S.l.], v. 13, n. 5, may 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6576>. Date accessed: 23 june 2025.
doi: https://doi.org/10.18103/mra.v13i5.6576.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Ware JE Jr, Gandek B, Guzer R, Deng N. Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL Disease Impact Scale (QDIS®). Health Qual Life Outcomes. 2016;14:84. doi: 10.1186/s12955-016-0483-x.
2. Food and Drug Administration (FDA). Draft Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, MD, Dec 2009.
3. European Medical Agency. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 2005, London, UK. Doc. Ref. EMEA/CHMP/EWP/139391/2004
4. Gvozdenovic BS, Mihailović-Vučinić V, Vuković M, et al. Effect of obesity on patient reported outcomes in sarcoidosis. Int J Tuberc Lung Dis. 2013;17(4):559–564.
5. Lapčević M, Gvozdenović BS, Stanković S, et al. Health-related quality of life of general practitioners – family physicians in southeastern Europe. Srp Arh Celok Lek. 2008;136(7-8):397-405.
6. Cox C, Donohue J, Brown C, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125:997-1004.
7. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81-7.
8. Gvozdenovic BS, Mihailovic-Vucinic V, Videnovic J, Zugic V, Ilic–Dudvarski A, Filipovic S. Quality of life and health status in sarcoidosis patients. Chapter 6. In: Hoffmann EC, ed. Health-related quality of life. New York: Nova Science Publishers, Inc., 2009:119–132.
9. Bradley C. Importance of differentiating health status from quality of life. Lancet. 2001;357(9249):7–8.
10. De Vries J, Wirnsberger RM. Fatigue, quality of life and health status in sarcoidosis. Eur Respir Mon. 2005;32:92–104.
11. Peters CML, de Vries J, Lodder P, et al. Quality of Life and not Health Status Improves After Major Amputation in the Elderly Critical Limb Ischaemia Patient. Eur J Vasc Endovasc Surg. 2019;57(4):547-553.
12. Andenaes R, Moum T, Kalfoss MH, Wahl AK. Changes in health status, psychological distress, and quality of life in COPD patients after hospitalization. Qual Life Res. 2006;15(2):249-257.
13. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079. Doi: 10.1183/13993003.04079-2020.
14. Baughman RP, Barriuso R, Beyer K, et al. Sarcoidosis: patient treatment priorities. ERJ Open Res. 2018;4(4):00151-2018. Doi: 10.1183/23120541.00141-2018.
15. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149–173.
16. Michielsen HJ, Peros-Golubicic T, Drent M, et al. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration. 2007;74:401–405.
17. De Vries J, Drent M. Quality of Life and Health Status in Sarcoidosis: A Review. Semin Respir Crit Care Med. 2007;28(1):121-127.
18. Obi ON, Polite PY, Fish KM, et al. A Snapshot of United States Sarcoidosis Patients and their Perceived Disease Impact: Results of the Sarcoidosis Research Institute Survey. Lung. 2025;203(1):31. doi:10.1007/s00408-024-00761-8.
19. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med. 2003;168:323–329.
20. Mihailović-Vučinić V, Gvozdenović B, Stjepanović M, et al. Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia. J Bras Pneumol. 2016;42(2):99-105.
21. Dudvarski-Ilić A, Mihailovic-Vucinić V, Gvozdenović B, Zugić V, Milenković B, Ilić V. Health related quality of life regarding to gender in sarcoidosis. Coll Antropol. 2009;33(3):837-40.
22. Bourbonnais JM, Samavati L. Effect of gender on health related quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27:96–102.
23. Ware JE, Sherbourne CD. A 36-item Short-Form Health Survey (SF-36): conceptual framework and item selection. Med Care. 1992;30(6):473-483.
24. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321–1327.
25. Tanizawa K, Handa T, Nagai S, et al. Validation of the Japanese version of the Sarcoidosis Health Questionnaire: a cross-sectional study. Health Qual Life Outcomes. 2011;9:34. doi: 10.1186/1477-7525-9-34.
26. Judson MA, Chaudhry H, Louis A, Lee K, Yucel R The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med. 2015;109(4):526–531.
27. Judson MA, Mack M, Beaumont JL, Watt R, Barnathan ES, Victorson DE. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. Am J Respir Crit Care Med. 2015;191:786–95.
28. Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King’s Sarcoidosis Questionnaire for the assessment of health status. Thorax. 2013,68:57–65.
29. Baughman RP, Judson MA, Beaumont JL, at al. Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study. Ann Am Thorac Soc. 2021;18(3):477-485.
30. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: the Fatigue Assessment Scale (FAS). J Psychosom Res. 2003;54:345–352.
31. Gvozdenovic BS, Patel AS, Birring SS, Vucinic V, Vukovic M. Impact of gender on disease activity, pulmonary function and health status in sarcoidosis patients – King’s Sarcoidosis Questionnaire (KSQ). Abstract P413 Abstracts from the 23rd European Respiratory Society Annual Congress, Barcelona, Spain, September 7–11, 2013. Eur Respir J. 2013;42(Suppl 57).
32. Sintonen H, Pekurinen M. A fefteen-dimensional measure of health-related quality of life (15D) and its applications. In Walker SR, Rosser R, eds. Quality of life assessment: key issues in 1990s. Dordrecht: Kluwer Academic Publishers, 1993:185–195.
33. Medical Research Council. Questionnaire on Respiratory Symptoms: instructions to interviewers. MRC Committee on Environmental and Occupational Health. London: MRC, 1986.
34. Stjepanovic M, Mihailovic-Vucinic V, Gvozdenovic BS, et al. King’s Sarcoidosis Questionnaire (KSQ) – Validation study in Serbian speaking population of sarcoidosis patients. PLoS One. 2023;18(9):e0273126.
35. Judson MA, Preston S, Hu K, et al. Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis. Respir Med. 2019;152:14-19.
36. Kalkanis A, Yucel RM, Judson MA. The internal consistency of PRO fatigue instruments in sarcoidosis: Superiority of the PFI over the FAS. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30(1):60-64.
37. Gvozdenovic BS, Mihailovic-Vucinic V, Ilic–Dudvarski A, Zugic V, Judson MA. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med. 2008;102(11):1636–1642.
38. Gvozdenovic BS, Mihailovic-Vucinic V, Vukovic M, et al. Predictors of health status and symptoms impairment in sarcoidosis patients. Chapter 5. In: Connor MR and Stevens RS, eds. Sarcoidosis: Diagnosis, Epidemiology and Treatment Options. New York: Nova Science Publishers, Inc., 2012:95–110.
39. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85:751-758.
40. Žugić V, Videnović-Ivanov J, Gvozdenović B. St. George’s Respiratory Questionnaire (SGRQ) in sarcoidosis patients. Med Pregl. 2005;58(Suppl 1):71-74.
41. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-381.
42. Lo KH, Donohue J, Judson MA, Wu Y, Barnathan ES, Baughman RP; Sarcoidosis T-48 Investigators. The St. George’s Respiratory Questionnaire in Pulmonary Sarcoidosis. Lung. 2020;198(6):917-924.
43. Guber E, Wand O, Epstein Shochet G, Romem A, Shitrit D. The Short- and Long-Term Impact of Pulmonary Rehabilitation in Subjects with Sarcoidosis: A Prospective Study and Review of the Literature. Respiration. 2021;100(5):423-431.
44. Rosenbach M, Yeung H, Chu EY, et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol. 2013;149(5):550-556.
45. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE, Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43(7):1478-87.
46. Bardakci MI, Ayhan Albayrak G. Quality of life, fatigue and markers in sarcoidosis: A section from Turkey. Sarcoidosis Vasc Diffuse Lung Dis. 2024;41(4):e2024049.
47. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403–1409.
48. Gvozdenovic BS, Mihailovic-Vucinic VV, Vukovic MH, et al. Predictors of cough-specific and generic quality of life in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):158-168.
49. Birring SS, Prudon B, Carr A.J, Singh SJ, Morgan MDL, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58:339–343.
50. Development of the world health organization WHOQOL-BREF quality of life assessment. the WHOQOL group. Psychol Med 1998;28(3):551-558.
51. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.
52. De Vries, J. Beyond health status: construction and validation of the Dutch WHO Quality of Life Instrument. PhD thesis. Tilburg: Tilburg University; 1996.
53. Hoitsma E, De Vries J, van Santen-Hoeufft M, Faber CG, Drent M. Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(1):33-39.
54. Wirnsberger RM, de Vries J, Breteler MH, van Heck GL, Wouters EF, Drent M. Evaluation of quality of life in sarcoidosis patients. Respir Med. 1998;92(5):750-756.
55. Alilović M, Peros-Golubicić T, Radosević-Vidacek B, et al. WHOQOL-BREF questionnaire as a measure of quality of life in sarcoidosis. Coll Antropol. 2013;37(3):701-706.
56. Marcellis R, Van der Veeke M, Mesters I, et al. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(1):53-62.
57. Drent M, Marcellis R, Lenssen A, De Vries J. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):117-128.
58. Rossi A, Rucci P, Mauri M, et al. Validity and reliability of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire. Qual Life Res. 2005;14(10):2323–2328.
59. Goracci A, Fagiolini A, Martinucci M, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008;30(5):441-445.
60. Thunold RF, Løkke A, Cohen AL, Ole H, Bendstrup E. Patient reported outcome measures (PROMs) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):2-17.
61. Obi ON. Health-Related Quality of Life in Sarcoidosis. Semin Respir Crit Care Med. 2020;41(5):716-732.
62. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147–153.
63. Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJR, Sijtsma K. Examination of the dimensionality of fatigue: the construction of the Fatigue Assessment Scale (FAS). Eur J Psychol Assess. 2004;20(1):39–48.
64. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40(1):255–263.
65. Jastrzębski D, Ziora D, Lubecki M, et al. Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life. Adv Exp Med Biol. 2015;833:31-36.
66. de Kleijn WP, De Vries J, Wijnen PA, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med. 2011;105(9):1388-1395.
67. Mihailovic-Vucinic V, Stjepanovic M, Milenkovic BA, Filipovic SD, Gvozdenovic B. The Correlation Between PET Scan Findings and Fatigue in Sarcoidosis. Abstract Abstracts from the 2019 International Conference, May 17-22, Dallas, Texas, American Thoracic Society. Am J Respir Crit Care Med. 2019;199:A3066.
68. Vucinic V, Mijailovic M, Sternic N, et al. Transcranial ultrasound (TCS) in sarcoidosis - relation to fatigue, depression and anxiety. Abstract E7. Abstracts from the 2nd Joint Meeting of WASOG and BAL, June 15-18, 2011, Maastricht, the Netherlands. https://www.wasog.org/dynamic/media/78/documents/abstracts_wasogbal2011.pdf
69. Gvozdenovic BS, Mihailovic-Vucinic V, Vukovic M, et a. Vitamin D deficiency, fatigue, and persistent cough as independent predictors of depressive symptoms in sarcoidosis patients. J Med Biochem. 2025;44(2):1-12. Doi: https://doi.org/10.5937/jomb0-54015
70. Deale A, Chalder T, Marks I, et al. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry. 1997;154:408–414.
71. Gvozdenović B, Mihailović-Vučinić V, Vukelić S, Tišma S, Mladenović V, Rovčanin Z. Importance of fatigue measurement in chronic diseases. Opšta medicina. 2010;16(1-2):21–9. https://scindeks.ceon.rs/article.aspx?artid=0354-71321002021G&lang=en
72. Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest. 2001;120(1):102–108.
73. Obi ON, Judson MA, Birring SS, et al. Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). Respir Med. 2022;191:106436.
74. Gvozdenovic BS, Vucinic V, Vukovic M. Measuring properties of different dyspnea instruments in sarcoidosis. Abstract P420 Abstracts from the 23rd European Respiratory Society (ERS) Annual Congress, Barcelona, Spain, September 7–11, 2013. Eur Respir J. 2013;42(Suppl 57).
75. Stenton C. The MRC breathlessness scale. Occup Med (Lond). 2008;58(3):226-227.
76. Gvozdenovic B, Mihailovic-Vucinic V, Zugic V, Vukovic, M. Predictors of health status in sarcoidosis patients. Abstract P590 Abstracts from the 20th European Respiratory Society (ERS) Annual Congress, Barcelona, Spain, September 18–22, 2010. Eur Respir J. 2010;36(Suppl 54):84s.
77. Gupta R, Baughman RP, Nathan SD, et al. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respir Med. 2022 May;196:106801.
78. Mahler DA, Witek Jr TJ. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99-103.
79. Witek Jr TJ, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol. 2003;56(3):248-255.
80. Sinha A, Lee KK, Rafferty GF, et al. Predictors of objective cough frequency in pulmonary sarcoidosis. Eur Respir J. 2016;47(5):1461-1471.
81. Bottine A, Grandjean J, Standaert M, Abdellaoui A, Reychler G. A systematic review of the psychometric properties of the Leicester Cough Questionnaires based on the COSMIN guidelines. Respir Med. 2024;231:107739. doi: 10.1016/j.rmed.2024.107739.
82. Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009;34(1):125-131.
83. Berkhof FF, Boom LN, ten Hertog NE, et al. The validity and precision of the leicester cough questionnaire in COPD patients with chronic cough. Health Qual Life Outcomes. 2012;10:4.
84. Del Corral T, Percegona J, Lopez N, et al. Validity of a Spanish Version of the Leicester Cough Questionnaire in Children With Cystic Fibrosis. Arch Bronconeumol. 2016;52(2):63-69.
85. Gvozdenović BS, Mihailović-Vučinić VV, Vuković MH, Stjepanović MI, Mihailović SV, Marić NB. Psychometric characteristics of the Serbian version of the Leicester cough questionnaire in sarcoidosis patients. Hospital Pharm Int Multidiciplinary J. 2019;6(1):728–737. doi:10.5937/hpimj1901728G
86. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med. 2001;163(2):329-334.
87. Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(2):147-153.
88. de Kleijn WP, Drent M, De Vries J. Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Br J Health Psychol. 2013;18(2):439-452.
89. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas. 1977;1(3):385–401. doi.org/10.1177/014662167700100306.
90. Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29(4):413–420.
91. Kato N, Kinugawa K, Shiga T, et al. Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction. J Cardiol. 2012;60(1):23–30.
92. Barry LC, Abou JJ, Simen AA, Gill TM. Under-treatment of depression in older persons. J Affect Disord. 2012;136(3):789–796.
93. Vucinic V, Filipovic S, Zugic V, Videnovic J, Gvozdenovic B. Depression in sarcoidosis - CES-D scale in sarcoidosis patients (Abstract) CHEST 2007 Scientific Highlights: Abstracts of Original Investigations and Case Reports, October 20-25, 2007, Chicago, IL. Chest. 2007;132(4 Suppl):586S–587S.
94. Culver DA, Aryal S, Barney J, et al. Efzofitimod for the Treatment of Pulmonary Sarcoidosis. Chest. 2023;163(4):881-890.
95. Kahlmann V, Janssen Bonás M, Moor CC, et al. Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. BMC Pulm Med. 2020;20(1):271. doi: 10.1186/s12890-020-01290-9.
96. Kahlmann V, Moor CC, Veltkamp M, Wijsenbeek MS. Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population. Chron Respir Dis. 2021;18:14799731211031935.
97. Kahlmann V, Janssen Bonás M, Moor CC, et al. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. N Engl J Med. 2025 May 18. doi: 10.1056/NEJMoa2501443. Online ahead of print.
98. Sharp M, Brown T, Chen ES, Rand CS, Moller DR, Eakin MN. Association of Medication Adherence and Clinical Outcomes in Sarcoidosis. Chest. 2020;158(1):226-233.
99. Baker MC, Horomanski A, Wang Y, et al. A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis. Rheumatology (Oxford). 2024;63(5):1297-1304.
100. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. J Pain Symptom Manage. 1997;13:63-74.
101. Mirsaeidi M, Baughman RP, Sahoo D, Tarau E. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis. Pulm Ther. 2023;9(2):237-253.
102. Vis R, van de Garde EMW, Meek B, Korenromp IHE, Grutters JC. Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis. Respir Med. 2020;165:105936.
103. Frye BC, Rump IC, Uhlmann A, et al. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial. Contemp Clin Trials Commun. 2020;19:100575.
104. Fraser SD, Thackray-Nocera S, et al. Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial. ERJ Open Res. 2020;6(4):00534-2020.
105. Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:90–98.
2. Food and Drug Administration (FDA). Draft Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, MD, Dec 2009.
3. European Medical Agency. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 2005, London, UK. Doc. Ref. EMEA/CHMP/EWP/139391/2004
4. Gvozdenovic BS, Mihailović-Vučinić V, Vuković M, et al. Effect of obesity on patient reported outcomes in sarcoidosis. Int J Tuberc Lung Dis. 2013;17(4):559–564.
5. Lapčević M, Gvozdenović BS, Stanković S, et al. Health-related quality of life of general practitioners – family physicians in southeastern Europe. Srp Arh Celok Lek. 2008;136(7-8):397-405.
6. Cox C, Donohue J, Brown C, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125:997-1004.
7. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81-7.
8. Gvozdenovic BS, Mihailovic-Vucinic V, Videnovic J, Zugic V, Ilic–Dudvarski A, Filipovic S. Quality of life and health status in sarcoidosis patients. Chapter 6. In: Hoffmann EC, ed. Health-related quality of life. New York: Nova Science Publishers, Inc., 2009:119–132.
9. Bradley C. Importance of differentiating health status from quality of life. Lancet. 2001;357(9249):7–8.
10. De Vries J, Wirnsberger RM. Fatigue, quality of life and health status in sarcoidosis. Eur Respir Mon. 2005;32:92–104.
11. Peters CML, de Vries J, Lodder P, et al. Quality of Life and not Health Status Improves After Major Amputation in the Elderly Critical Limb Ischaemia Patient. Eur J Vasc Endovasc Surg. 2019;57(4):547-553.
12. Andenaes R, Moum T, Kalfoss MH, Wahl AK. Changes in health status, psychological distress, and quality of life in COPD patients after hospitalization. Qual Life Res. 2006;15(2):249-257.
13. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079. Doi: 10.1183/13993003.04079-2020.
14. Baughman RP, Barriuso R, Beyer K, et al. Sarcoidosis: patient treatment priorities. ERJ Open Res. 2018;4(4):00151-2018. Doi: 10.1183/23120541.00141-2018.
15. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149–173.
16. Michielsen HJ, Peros-Golubicic T, Drent M, et al. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration. 2007;74:401–405.
17. De Vries J, Drent M. Quality of Life and Health Status in Sarcoidosis: A Review. Semin Respir Crit Care Med. 2007;28(1):121-127.
18. Obi ON, Polite PY, Fish KM, et al. A Snapshot of United States Sarcoidosis Patients and their Perceived Disease Impact: Results of the Sarcoidosis Research Institute Survey. Lung. 2025;203(1):31. doi:10.1007/s00408-024-00761-8.
19. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med. 2003;168:323–329.
20. Mihailović-Vučinić V, Gvozdenović B, Stjepanović M, et al. Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia. J Bras Pneumol. 2016;42(2):99-105.
21. Dudvarski-Ilić A, Mihailovic-Vucinić V, Gvozdenović B, Zugić V, Milenković B, Ilić V. Health related quality of life regarding to gender in sarcoidosis. Coll Antropol. 2009;33(3):837-40.
22. Bourbonnais JM, Samavati L. Effect of gender on health related quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27:96–102.
23. Ware JE, Sherbourne CD. A 36-item Short-Form Health Survey (SF-36): conceptual framework and item selection. Med Care. 1992;30(6):473-483.
24. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321–1327.
25. Tanizawa K, Handa T, Nagai S, et al. Validation of the Japanese version of the Sarcoidosis Health Questionnaire: a cross-sectional study. Health Qual Life Outcomes. 2011;9:34. doi: 10.1186/1477-7525-9-34.
26. Judson MA, Chaudhry H, Louis A, Lee K, Yucel R The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med. 2015;109(4):526–531.
27. Judson MA, Mack M, Beaumont JL, Watt R, Barnathan ES, Victorson DE. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. Am J Respir Crit Care Med. 2015;191:786–95.
28. Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King’s Sarcoidosis Questionnaire for the assessment of health status. Thorax. 2013,68:57–65.
29. Baughman RP, Judson MA, Beaumont JL, at al. Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study. Ann Am Thorac Soc. 2021;18(3):477-485.
30. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: the Fatigue Assessment Scale (FAS). J Psychosom Res. 2003;54:345–352.
31. Gvozdenovic BS, Patel AS, Birring SS, Vucinic V, Vukovic M. Impact of gender on disease activity, pulmonary function and health status in sarcoidosis patients – King’s Sarcoidosis Questionnaire (KSQ). Abstract P413 Abstracts from the 23rd European Respiratory Society Annual Congress, Barcelona, Spain, September 7–11, 2013. Eur Respir J. 2013;42(Suppl 57).
32. Sintonen H, Pekurinen M. A fefteen-dimensional measure of health-related quality of life (15D) and its applications. In Walker SR, Rosser R, eds. Quality of life assessment: key issues in 1990s. Dordrecht: Kluwer Academic Publishers, 1993:185–195.
33. Medical Research Council. Questionnaire on Respiratory Symptoms: instructions to interviewers. MRC Committee on Environmental and Occupational Health. London: MRC, 1986.
34. Stjepanovic M, Mihailovic-Vucinic V, Gvozdenovic BS, et al. King’s Sarcoidosis Questionnaire (KSQ) – Validation study in Serbian speaking population of sarcoidosis patients. PLoS One. 2023;18(9):e0273126.
35. Judson MA, Preston S, Hu K, et al. Quantifying the relationship between symptoms at presentation and the prognosis of sarcoidosis. Respir Med. 2019;152:14-19.
36. Kalkanis A, Yucel RM, Judson MA. The internal consistency of PRO fatigue instruments in sarcoidosis: Superiority of the PFI over the FAS. Sarcoidosis Vasc Diffuse Lung Dis. 2013; 30(1):60-64.
37. Gvozdenovic BS, Mihailovic-Vucinic V, Ilic–Dudvarski A, Zugic V, Judson MA. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med. 2008;102(11):1636–1642.
38. Gvozdenovic BS, Mihailovic-Vucinic V, Vukovic M, et al. Predictors of health status and symptoms impairment in sarcoidosis patients. Chapter 5. In: Connor MR and Stevens RS, eds. Sarcoidosis: Diagnosis, Epidemiology and Treatment Options. New York: Nova Science Publishers, Inc., 2012:95–110.
39. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85:751-758.
40. Žugić V, Videnović-Ivanov J, Gvozdenović B. St. George’s Respiratory Questionnaire (SGRQ) in sarcoidosis patients. Med Pregl. 2005;58(Suppl 1):71-74.
41. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-381.
42. Lo KH, Donohue J, Judson MA, Wu Y, Barnathan ES, Baughman RP; Sarcoidosis T-48 Investigators. The St. George’s Respiratory Questionnaire in Pulmonary Sarcoidosis. Lung. 2020;198(6):917-924.
43. Guber E, Wand O, Epstein Shochet G, Romem A, Shitrit D. The Short- and Long-Term Impact of Pulmonary Rehabilitation in Subjects with Sarcoidosis: A Prospective Study and Review of the Literature. Respiration. 2021;100(5):423-431.
44. Rosenbach M, Yeung H, Chu EY, et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol. 2013;149(5):550-556.
45. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE, Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43(7):1478-87.
46. Bardakci MI, Ayhan Albayrak G. Quality of life, fatigue and markers in sarcoidosis: A section from Turkey. Sarcoidosis Vasc Diffuse Lung Dis. 2024;41(4):e2024049.
47. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41:1403–1409.
48. Gvozdenovic BS, Mihailovic-Vucinic VV, Vukovic MH, et al. Predictors of cough-specific and generic quality of life in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):158-168.
49. Birring SS, Prudon B, Carr A.J, Singh SJ, Morgan MDL, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58:339–343.
50. Development of the world health organization WHOQOL-BREF quality of life assessment. the WHOQOL group. Psychol Med 1998;28(3):551-558.
51. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.
52. De Vries, J. Beyond health status: construction and validation of the Dutch WHO Quality of Life Instrument. PhD thesis. Tilburg: Tilburg University; 1996.
53. Hoitsma E, De Vries J, van Santen-Hoeufft M, Faber CG, Drent M. Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(1):33-39.
54. Wirnsberger RM, de Vries J, Breteler MH, van Heck GL, Wouters EF, Drent M. Evaluation of quality of life in sarcoidosis patients. Respir Med. 1998;92(5):750-756.
55. Alilović M, Peros-Golubicić T, Radosević-Vidacek B, et al. WHOQOL-BREF questionnaire as a measure of quality of life in sarcoidosis. Coll Antropol. 2013;37(3):701-706.
56. Marcellis R, Van der Veeke M, Mesters I, et al. Does physical training reduce fatigue in sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(1):53-62.
57. Drent M, Marcellis R, Lenssen A, De Vries J. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):117-128.
58. Rossi A, Rucci P, Mauri M, et al. Validity and reliability of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire. Qual Life Res. 2005;14(10):2323–2328.
59. Goracci A, Fagiolini A, Martinucci M, et al. Quality of life, anxiety and depression in sarcoidosis. Gen Hosp Psychiatry. 2008;30(5):441-445.
60. Thunold RF, Løkke A, Cohen AL, Ole H, Bendstrup E. Patient reported outcome measures (PROMs) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):2-17.
61. Obi ON. Health-Related Quality of Life in Sarcoidosis. Semin Respir Crit Care Med. 2020;41(5):716-732.
62. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147–153.
63. Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJR, Sijtsma K. Examination of the dimensionality of fatigue: the construction of the Fatigue Assessment Scale (FAS). Eur J Psychol Assess. 2004;20(1):39–48.
64. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J. 2012;40(1):255–263.
65. Jastrzębski D, Ziora D, Lubecki M, et al. Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life. Adv Exp Med Biol. 2015;833:31-36.
66. de Kleijn WP, De Vries J, Wijnen PA, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med. 2011;105(9):1388-1395.
67. Mihailovic-Vucinic V, Stjepanovic M, Milenkovic BA, Filipovic SD, Gvozdenovic B. The Correlation Between PET Scan Findings and Fatigue in Sarcoidosis. Abstract Abstracts from the 2019 International Conference, May 17-22, Dallas, Texas, American Thoracic Society. Am J Respir Crit Care Med. 2019;199:A3066.
68. Vucinic V, Mijailovic M, Sternic N, et al. Transcranial ultrasound (TCS) in sarcoidosis - relation to fatigue, depression and anxiety. Abstract E7. Abstracts from the 2nd Joint Meeting of WASOG and BAL, June 15-18, 2011, Maastricht, the Netherlands. https://www.wasog.org/dynamic/media/78/documents/abstracts_wasogbal2011.pdf
69. Gvozdenovic BS, Mihailovic-Vucinic V, Vukovic M, et a. Vitamin D deficiency, fatigue, and persistent cough as independent predictors of depressive symptoms in sarcoidosis patients. J Med Biochem. 2025;44(2):1-12. Doi: https://doi.org/10.5937/jomb0-54015
70. Deale A, Chalder T, Marks I, et al. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry. 1997;154:408–414.
71. Gvozdenović B, Mihailović-Vučinić V, Vukelić S, Tišma S, Mladenović V, Rovčanin Z. Importance of fatigue measurement in chronic diseases. Opšta medicina. 2010;16(1-2):21–9. https://scindeks.ceon.rs/article.aspx?artid=0354-71321002021G&lang=en
72. Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest. 2001;120(1):102–108.
73. Obi ON, Judson MA, Birring SS, et al. Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). Respir Med. 2022;191:106436.
74. Gvozdenovic BS, Vucinic V, Vukovic M. Measuring properties of different dyspnea instruments in sarcoidosis. Abstract P420 Abstracts from the 23rd European Respiratory Society (ERS) Annual Congress, Barcelona, Spain, September 7–11, 2013. Eur Respir J. 2013;42(Suppl 57).
75. Stenton C. The MRC breathlessness scale. Occup Med (Lond). 2008;58(3):226-227.
76. Gvozdenovic B, Mihailovic-Vucinic V, Zugic V, Vukovic, M. Predictors of health status in sarcoidosis patients. Abstract P590 Abstracts from the 20th European Respiratory Society (ERS) Annual Congress, Barcelona, Spain, September 18–22, 2010. Eur Respir J. 2010;36(Suppl 54):84s.
77. Gupta R, Baughman RP, Nathan SD, et al. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respir Med. 2022 May;196:106801.
78. Mahler DA, Witek Jr TJ. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99-103.
79. Witek Jr TJ, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol. 2003;56(3):248-255.
80. Sinha A, Lee KK, Rafferty GF, et al. Predictors of objective cough frequency in pulmonary sarcoidosis. Eur Respir J. 2016;47(5):1461-1471.
81. Bottine A, Grandjean J, Standaert M, Abdellaoui A, Reychler G. A systematic review of the psychometric properties of the Leicester Cough Questionnaires based on the COSMIN guidelines. Respir Med. 2024;231:107739. doi: 10.1016/j.rmed.2024.107739.
82. Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009;34(1):125-131.
83. Berkhof FF, Boom LN, ten Hertog NE, et al. The validity and precision of the leicester cough questionnaire in COPD patients with chronic cough. Health Qual Life Outcomes. 2012;10:4.
84. Del Corral T, Percegona J, Lopez N, et al. Validity of a Spanish Version of the Leicester Cough Questionnaire in Children With Cystic Fibrosis. Arch Bronconeumol. 2016;52(2):63-69.
85. Gvozdenović BS, Mihailović-Vučinić VV, Vuković MH, Stjepanović MI, Mihailović SV, Marić NB. Psychometric characteristics of the Serbian version of the Leicester cough questionnaire in sarcoidosis patients. Hospital Pharm Int Multidiciplinary J. 2019;6(1):728–737. doi:10.5937/hpimj1901728G
86. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med. 2001;163(2):329-334.
87. Yeager H, Rossman MD, Baughman RP, et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(2):147-153.
88. de Kleijn WP, Drent M, De Vries J. Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis. Br J Health Psychol. 2013;18(2):439-452.
89. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas. 1977;1(3):385–401. doi.org/10.1177/014662167700100306.
90. Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29(4):413–420.
91. Kato N, Kinugawa K, Shiga T, et al. Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction. J Cardiol. 2012;60(1):23–30.
92. Barry LC, Abou JJ, Simen AA, Gill TM. Under-treatment of depression in older persons. J Affect Disord. 2012;136(3):789–796.
93. Vucinic V, Filipovic S, Zugic V, Videnovic J, Gvozdenovic B. Depression in sarcoidosis - CES-D scale in sarcoidosis patients (Abstract) CHEST 2007 Scientific Highlights: Abstracts of Original Investigations and Case Reports, October 20-25, 2007, Chicago, IL. Chest. 2007;132(4 Suppl):586S–587S.
94. Culver DA, Aryal S, Barney J, et al. Efzofitimod for the Treatment of Pulmonary Sarcoidosis. Chest. 2023;163(4):881-890.
95. Kahlmann V, Janssen Bonás M, Moor CC, et al. Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. BMC Pulm Med. 2020;20(1):271. doi: 10.1186/s12890-020-01290-9.
96. Kahlmann V, Moor CC, Veltkamp M, Wijsenbeek MS. Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population. Chron Respir Dis. 2021;18:14799731211031935.
97. Kahlmann V, Janssen Bonás M, Moor CC, et al. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. N Engl J Med. 2025 May 18. doi: 10.1056/NEJMoa2501443. Online ahead of print.
98. Sharp M, Brown T, Chen ES, Rand CS, Moller DR, Eakin MN. Association of Medication Adherence and Clinical Outcomes in Sarcoidosis. Chest. 2020;158(1):226-233.
99. Baker MC, Horomanski A, Wang Y, et al. A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis. Rheumatology (Oxford). 2024;63(5):1297-1304.
100. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. J Pain Symptom Manage. 1997;13:63-74.
101. Mirsaeidi M, Baughman RP, Sahoo D, Tarau E. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis. Pulm Ther. 2023;9(2):237-253.
102. Vis R, van de Garde EMW, Meek B, Korenromp IHE, Grutters JC. Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis. Respir Med. 2020;165:105936.
103. Frye BC, Rump IC, Uhlmann A, et al. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial. Contemp Clin Trials Commun. 2020;19:100575.
104. Fraser SD, Thackray-Nocera S, et al. Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial. ERJ Open Res. 2020;6(4):00534-2020.
105. Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:90–98.